Insulin-dependent. Rapamycin-resistant?;Insulinodependencia, ¿rapamicina-resistencia?

Revista Espanola de Cardiologia

Volumn 59, Issue 2, 2006, Pages 91-93

  Sabaté, Manel ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN; IMMUNOSUPPRESSIVE AGENT;

CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; HEALTH CARE COST; HUMAN; IN-STENT RESTENOSIS; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; SYSTEMATIC REVIEW; ANGIOCARDIOGRAPHY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG DELIVERY SYSTEM; ECONOMICS; FEMALE; HEART INFARCTION; HYPERTENSION; INCIDENCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; REGISTER; RESTENOSIS; RISK FACTOR; STATISTICAL ANALYSIS; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; MALE; META-ANALYSIS; MYOCARDIAL INFARCTION; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; RISK FACTORS; SIROLIMUS; STENTS; TREATMENT OUTCOME;

EID: 33645565421     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13084634     Document Type: Editorial

References (19)

1. López-Palop R, Moreu J, Fernández-Vazquez F, Hernández R. Registro Español de Hemodinámica y Cardiología Intervencionista. XIV Informe Oficial de la Sección de Hemodinámica y Cardiología Intervencionista de la Sociedad Española de Cardiología (1990-2004). Rev Esp Cardiol. 2005;58:1318-34.
2. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, et al; RAVEL Study Group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346:1773-80.
3. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23.
4. Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, et al; TAXUS II Study Group. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation. 2003;108:788-94.
5. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31.
6. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, et al; TAXUS VI Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation. 2005;112:3306-13.
7. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al; TAXUS V Investigators. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-23.
8. Oliva G, Espallargues M, Pons JMV. Stents recubiertos de fármacos antiproliferativos: revisión sistemática del beneficio y estimación del impacto presupuestario. Rev Esp Cardiol. 2004;57:617-28.
9. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al; BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366: 921-9.
10. Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634-40.
11. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation. 2004;109:1942-7.
12. De la Torre JM, Burgos V, González-Enríquez S, Cobo M, Zueco J, Figueroa A, et al. Stent liberador de rapamicina en el tratamiento de lesiones coronaries con alto riesgo de reestenosis. Seguimiento clínico a 6 meses de los primeros 100 pacientes. Rev Esp Cardiol. 2004;57:116-22.
13. Ruiz-Nodar JM, Frutos A, Carrillo P, Morillas P, Valero R, Rodríguez JA, et al. Utilización del stent recubierto de rapamicina en la revascularización de lesiones complejas: estudio con seguimiento clínico y angiográfico. Rev Esp Cardiol. 2004;57:123-9.
14. De la Torre JM, Sainz F, Ruisánchez C, Zueco J, Figueroa A, Colman T. Tratamiento de lesiones con alto riesgo de reestenosis. Estudio comparative en 300 pacientes del stent liberador de rapamicina, el stent con polímero liberador de paclitaxel y el stent convencional. Rev Esp Cardiol. 2005;58:262-9.
15. Berenguer A, Mainar V, Bordes P, Valencia J, Gomez S. Utilidad de los stents recubiertos de rapamicina en pacientes diabéticos con lesiones coronaries complejas. Rev Esp Cardiol. 2006;59:117-24.
16. Berenguer A, Mainar V, Bordes P, Valencia J, Gómez S, Lozano T. Incidence and predictors of restenosis after sirolimus-eluting stent implantation in high-risk patients. Am Heart J. 2005;150:536-42.
17. Moussa I, Leon MB, Baim DS, O'Neill WW, Popma JJ, Buchbinder M, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation. 2004;109:2273-8.
18. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gómez-Hospital JA, Alfonso F, Hernández-Antolin R, et al; DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005;112:2175-83.
19. Ong AT, Aoki J, Van Mieghem CA, Rodríguez Granillo GA, Valgimigli M, Tsuchida K, et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus-versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol. 2005;96:358-62.